After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.
Stocks Info
The company is listed on the NASDAQ and operates within the Biotechnology industry segment. The current market capitalization of Arcutis Biotherapeutics Inc is $2.37B. A total of 2.14 million shares were traded on the day, compared to an average of 1.77M shares.
In the most recent transaction, Edwards Larry Todd sold 4,504 shares of ARQT for 20.04 per share on Oct 02 ’25. After the transaction, the insider now owns 178,897 company shares. In a previous transaction on Oct 01 ’25, Watanabe Todd sold 24,261 shares at 19.33 per share. ARQT shares that the insider owns now total 867,179.
Among the insiders who sold shares, Watanabe Todd disposed of 20,739 shares on Oct 02 ’25 at a per-share price of $20.04. This resulted in the insider holding 846,440 shares of ARQT after the transaction. In another insider transaction, Welgus Howard G. sold 10,000 shares at $18.92 per share on Oct 01 ’25. Company shares held by the Director now total 99,744.
It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. In terms of 52-week highs and lows, ARQT has a high of $21.30 and a low of $8.03.
As of this writing, ARQT has an earnings estimate of -$0.1 per share for the current quarter. EPS was calculated based on a consensus of 6.0 estimates, with a high estimate of -$0.05 per share and a lower estimate of -$0.13. The company reported an EPS of -$0.33 in the last quarter
Balance Sheet Annually/Quarterly
An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information. ARQT’s latest balance sheet shows that the firm has $387.06M in Cash & Short Term Investments as of fiscal 2021. There were $77.56M in debt and $33.33M in liabilities at the time. Its Book Value Per Share was $1.16, while its Total Shareholder’s Equity was $297.68M.
Analysts Opinion
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ARQT is Buy with a score of 4.44.
